Fresenius Kabi's Neulasta biosimilar Stimufend gets approval in EU
olrat/iStock Editorial via Getty Images         

The European Commission granted marketing authorization to Fresenius' (OTCPK:FSNUF) (OTCPK:FSNUY) Kabi's Stimufend (pegfilgrastim),Â a biosimilar to Amgen's (AMGN) Neulasta.
The approval was forÂ all indications of the reference product.
The company said Stimufend stimulates the growth of certain white blood cells that play a role in preventing or fighting infections, which often pose a life-threatening risk in patients receiving myelosuppressive chemotherapy.
Fresenius said it is the first biosimilar molecule approved for cancer therapy and the second biosimilar in Kabi's portfolio to be approved in Europe.
The company added that it is expanding its product range geared towards autoimmune diseases and oncology.